Literature DB >> 32112196

Osteoporosis screening using computed tomography for men with prostate cancer: results of a prospective study.

Andrew M McDonald1,2, Eddy S Yang3, Kenneth G Saag4, Emily B Levitan5, Nicole C Wright5, John B Fiveash3, Soroush Rais-Bahrami6, Smita Bhatia7,8.   

Abstract

We performed a prospective study using both FRAX and computed tomography to screen for osteoporosis in men undergoing radiation for prostate cancer. We found that implementing routine computed tomography (CT)-based screening was feasible in the setting of a prospective study, but the yield of osteoporosis identification was low in this population.
PURPOSE: Men with prostate cancer (PCa) are at increased risk of hip fracture for multiple reasons. Estimation of hip fracture risk with the FRAX tool is currently recommended, but FRAX alone may not identify a portion of men with osteoporosis. We hypothesized that adding bone mineral density (BMD) screening using CT to FRAX is feasible and would identify more men with osteoporosis.
METHODS: Men with PCa scheduled to undergo CT simulation for radiation treatment were enrolled in a single-arm prospective study. The mean attenuation of the mid-L5 vertebral body trabecular bone (L5CT) was calculated on a single slice using the radiation simulation CT scan. The 10-year risk of hip fracture was calculated using the FRAX tool. Dual energy X-ray absorptiometry (DXA) was performed for men whose L5CT measurement was less than 130 Hounsfield units (HU).
RESULTS: A total of 98 eligible men were enrolled and underwent FRAX and CT screening. The median 10-year risk of hip fracture was 1.1% and exceeded 3% in 16 cases; the median L5CT was 162.28 HU (range 55.6-526.1 HU). DXA scan was completed in 15 men who had L5CT < 130 HU but 10-year calculated hip fracture risk < 3%, 1 of whom was found to have osteoporosis (T-score ≤ -2.5).
CONCLUSIONS: Implementing CT-based BMD screening was feasible in the setting of a prospective study for men receiving radiation for PCa, but fewer cases than anticipated of osteoporosis were identified.

Entities:  

Keywords:  Computed tomography; Opportunistic screening; Prostate cancer

Mesh:

Year:  2020        PMID: 32112196      PMCID: PMC7402416          DOI: 10.1007/s11657-020-0711-1

Source DB:  PubMed          Journal:  Arch Osteoporos            Impact factor:   2.617


  29 in total

1.  Combining Computed Tomography-Based Bone Density Assessment with FRAX Screening in Men with Prostate Cancer.

Authors:  Andrew M McDonald; Joseph A Jones; Rex A Cardan; Kenneth S Saag; David L Mayhew; John B Fiveash
Journal:  J Clin Densitom       Date:  2016-05-27       Impact factor: 2.617

Review 2.  Osteoporosis diagnosis in men: the T-score controversy revisited.

Authors:  Neil Binkley; Robert Adler; John P Bilezikian
Journal:  Curr Osteoporos Rep       Date:  2014-12       Impact factor: 5.096

3.  Cost-Effectiveness of Osteoporosis Screening Using Biomechanical Computed Tomography for Patients With a Previous Abdominal CT.

Authors:  Maria Pisu; David L Kopperdahl; Cora E Lewis; Kenneth G Saag; Tony M Keaveny
Journal:  J Bone Miner Res       Date:  2019-03-24       Impact factor: 6.741

4.  Hounsfield units for assessing bone mineral density and strength: a tool for osteoporosis management.

Authors:  Joseph J Schreiber; Paul A Anderson; Humberto G Rosas; Avery L Buchholz; Anthony G Au
Journal:  J Bone Joint Surg Am       Date:  2011-06-01       Impact factor: 5.284

5.  Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma.

Authors:  J F Maillefert; J Sibilia; F Michel; C Saussine; R M Javier; C Tavernier
Journal:  J Urol       Date:  1999-04       Impact factor: 7.450

6.  Prevention and management of osteoporosis in men receiving androgen deprivation therapy: a survey of urologists and radiation oncologists.

Authors:  Shabbir M H Alibhai; Sameera Rahman; Padraig R Warde; Michael A S Jewett; Taha Jaffer; Angela M Cheung
Journal:  Urology       Date:  2006-07       Impact factor: 2.649

7.  Fracture risk in Danish men with prostate cancer: a nationwide register study.

Authors:  Bo Abrahamsen; Morten F Nielsen; Peter Eskildsen; Jens Thorup Andersen; Steen Walter; Kim Brixen
Journal:  BJU Int       Date:  2007-10       Impact factor: 5.588

8.  Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

Authors:  B J Kiratli; S Srinivas; I Perkash; M K Terris
Journal:  Urology       Date:  2001-01       Impact factor: 2.649

9.  Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.

Authors:  Christopher W Ryan; Dezheng Huo; Kathryn Bylow; Laurence M Demers; Walter M Stadler; Tara O Henderson; Nicholas J Vogelzang
Journal:  BJU Int       Date:  2007-07       Impact factor: 5.588

10.  Clinician's Guide to Prevention and Treatment of Osteoporosis.

Authors:  F Cosman; S J de Beur; M S LeBoff; E M Lewiecki; B Tanner; S Randall; R Lindsay
Journal:  Osteoporos Int       Date:  2014-08-15       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.